Viewing entries tagged

No Restrictions for Hep C


Great news!

As of January 1, 2019, Hawaii State Medicaid (MedQUEST) has removed requirements on fibrosis and sobriety in its guidance for hepatitis C medications. This is in alignment with recommendations from the American Association for the Study of Liver Diseases, and it will provide more people access to life-saving treatment.

We will continue to work with patients, providers, and insurance plans to ensure that these new recommendations are implemented. Please contact us if you would like to report any issues with access.

For more clinician resources, click here.

Hawaii Medicaid Gets D+

On October 23, 2017, the National Viral Hepatitis Roundtable (NVHR) and the Center for Health Law and Policy Innovation of Harvard Law School (CHLPI) released “Hepatitis C: State of Medicaid Access”. The report ( grades each state Medicaid program, as well as the District of Columbia and Puerto Rico, based on three types of treatment restrictions for hepatitis C: 1) liver disease progression (fibrosis) restrictions, 2) sobriety/substance use requirements, and 3) prescriber limitations.

Sadly, Hawaii got a grade of D+, along more than half of Medicaid programs that received a “D” or an “F”.  As a coalition, we recognize that Hawaii's low grade means we have a lot more work to do.  Let's move towards a hep C cure for everyone!